June 27, 2016
(New York Times) – A high-ranking Senate Democrat is pushing for more answers on why doctors and patient advocates with financial ties to the pharmaceutical industry came to serve on a panel that advises the federal government on pain issues. Sen. Ron Wyden says he is “even more concerned” about these apparent conflicts of interest after receiving a response from the National Institutes of Health, which vetted and selected the panel members. In a letter sent Thursday to the Obama administration’s top health official, Wyden requests a series of documents related to the pain panel, including financial disclosure forms filled out by its members.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.